Published in Clinical Oncology Week, March 24th, 2008
"The activity of Essiac (R) was measured using established assays to assess anti-oxidant, fibrinolytic, anti-microbial, anti-inflammatory, immune modulation, cells-pecific cytotoxicity, and impact on cytochrome P450 (CYP450) enzyme pathways. Essiac (R) exhibited significant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.